阿伐曲泊帕治疗肿瘤治疗相关血小板减少症的疗效及耐受性研究  

Efficacy and tolerability of avatrombopag in treatmeat for cancer therapy-related thrombopenia

作　　者：王玲燕 金剑英[1] 谢静静[1] 郭群依[1] WANG Lingyan;JIN Jianying;XIE Jingjing;GUO Qunyi(Department of Hematology Oncology,Taizhou Hospital of Zhejiang Province,Taizhou 317000,China)

机构地区：[1]浙江省台州医院血液肿瘤内科,317000

出　　处：《浙江医学》2023年第14期1528-1531,共4页Zhejiang Medical Journal

摘　　要：目的观察阿伐曲泊帕治疗肿瘤治疗相关血小板减少症(CTRT)的疗效及耐受性。方法回顾性分析2020年11月至2022年5月浙江省台州医院收治的38例CTRT患者。所有患者均接受阿伐曲泊帕片口服治疗,40 mg/d,1次/d。记录并比较患者使用阿伐曲泊帕治疗前、后的PLT变化,治疗效果及不良反应情况。根据升血小板治疗是否有效将患者分为有效组34例和无效组4例,比较两组不同临床特征CTRT患者临床资料。结果共纳入38例CTRT患者,使用阿伐曲泊帕治疗前PLT为(37.84±2.85)×10^(9)/L,中位血小板治疗有效时间为7(2,12)d,停药时PLT为(127.34±0.45)×10^(9)/L;阿伐曲泊帕升血小板治疗的有效率为89.5%(34/38),治疗期间29.0%(11/38)的患者接受了血小板输注,所有患者均未发生出血事件。所有患者均未出现明显不良反应。不同性别、治疗方式、治疗时长以及肿瘤分期的CTRT患者阿伐曲泊帕治疗后升血小板有效率比较差异均无统计学意义(均P>0.05)。结论阿伐曲泊帕对CTRT有一定疗效,且口服方便、耐受性良好,可作为CTRT患者的新型治疗选择。Objective To investigate the efficacy and tolerability of avatrombopag in treatment of cancer therapyrelated thrombopenia(CTRT).Methods Clinical data of 38 patients with CTRT treated with avatrombopag(40 mg/d)in Taizhou Hospital of Zhejiang Province from November 2020 to May 2022 were retrospectively analyzed.The changes in PLT before and after treatment,therapeutic effects and adverse reactions of avatrombopag were recorded and analyzed.Patients were divided into effective group and ineffective group according to the effectiveness of platelet elevation,and the clinical data of CTRT patients with different clinical characteristics were compared betwween the two groups.Results The mean levels of PLT before and after avatrombopag treatment were(37.84±2.85)×10^(9)/L and(127.34±0.45)×10^(9)/L,respectivel with a median PLT recovery time of 7(2,12)d.The efficacy rate of avatrombopag was 89.5%(34/38),11 patients(29.0%)received PLT transfusions,and no bleeding occurred in all patients.Avatrombopag was well tolerated by all patients and none had any significant adverse effects.There was no significant difference in the response rate of PLT elevation among CTRT patients with different genders,treatment methods,treatment duration and tumor stages(all P>0.05).Conclusion Avatrombopag is effective in the treatment of CTRT,which is well tolerated and can be used as a therapeutic option for refractory CTRT patients.

关 键 词：肿瘤治疗相关血小板减少症 阿伐曲泊帕 疗效 

分 类 号：R730.5[医药卫生—肿瘤] R558.2[医药卫生—临床医学]